Introduction {#section1-1087054719841129}
============

ADHD is increasingly recognized as a lifelong condition, affecting an estimated 9% of children ([@bibr12-1087054719841129]) and 4.4% of adults ([@bibr21-1087054719841129]) in the United States.

Numerous studies have investigated the negative impact of ADHD in adults on educational attainment, employability, and productivity in the workplace, as well as on functional ability, self-esteem, and social functioning ([@bibr4-1087054719841129]; [@bibr10-1087054719841129]; [@bibr11-1087054719841129]; [@bibr17-1087054719841129]). One study involving a large manufacturing company found that ADHD was associated with a 4% to 5% reduction in work performance (*p* = .001), as well as greater odds of sickness absence (*p* = .013) and workplace accident injuries (*p* = .024) ([@bibr22-1087054719841129]). Another study demonstrated a higher rate of work-related injury claims by individuals with ADHD than by individuals without ADHD (21.5% vs. 15.7%; *p* \< .0001; [@bibr18-1087054719841129]). The loss of productivity observed in adults with ADHD may be partly caused by poor time management, procrastination, and distractibility, factors which also have a negative impact on quality of life ([@bibr8-1087054719841129]). Quality of life can be further impaired by comorbidities such as anxiety and mood disorders, which are common in adults with ADHD ([@bibr21-1087054719841129]; [@bibr29-1087054719841129]). Furthermore, adults with ADHD have impaired social functioning, including problems sustaining stable relationships, antisocial behaviors, and lower self-esteem, compared with individuals without the condition ([@bibr7-1087054719841129]).

Historically, ADHD was perceived to be a childhood disorder that individuals would outgrow as they matured ([@bibr9-1087054719841129]). In fact, approximately 50% to 75% of children with ADHD continue to meet diagnostic criteria for the disorder in later life as adolescents and also as adults ([@bibr25-1087054719841129]). However, few published data are available on the burden of ADHD symptoms on undiagnosed adults. In 2007, it was estimated that less than 20% of adults with ADHD are diagnosed and/or treated ([@bibr26-1087054719841129]). Both the presence of common comorbidities, such as depression and anxiety, and variability in presentation throughout development can complicate diagnosis ([@bibr34-1087054719841129]). A lack of diagnosis is reported to impair psychological health ([@bibr3-1087054719841129]).

The Validate Attitudes and Lifestyle Issues in Depression, ADHD and Troubles with Eating (VALIDATE) study of the 2012 and 2013 U.S. National Health and Wellness Survey was undertaken to estimate the symptom burden of ADHD in a nationally representative sample of U.S. adults. The study collected information on ADHD diagnosis, and assessed ADHD symptoms, health-related quality of life (HRQoL), functioning, and productivity.

Using the VALIDATE study data, the aim of our analysis was to explore the association between diagnosis and outcomes in adults with symptoms of ADHD. The impact of an ADHD diagnosis on HRQoL, work productivity, functioning, and self-esteem in U.S. adults was estimated by comparing these outcomes in respondents diagnosed with ADHD at some point in their life with those in respondents with self-reported ADHD-like symptoms but no previous clinical diagnosis.

Method {#section2-1087054719841129}
======

Study Design {#section3-1087054719841129}
------------

The overall study procedures and recruited sample have been previously described ([@bibr14-1087054719841129]; [@bibr27-1087054719841129]). Briefly, a representative sample of 69,972 U.S. adults aged 18 years or older who completed the 2012 and 2013 U.S. National Health and Wellness Survey were invited to participate in the VALIDATE study (conducted between 9 October and 29 October 2013). The study protocol was reviewed and approved by an Institutional Review Board (Sterling, Institutional Review Board \#4509) before study data collection. Study participants provided consent before completing the survey and received panel points to be used for consumer goods (e.g., gift cards) as reimbursement for their time. The information collected was de-identified to ensure respondent privacy and confidentiality.

The VALIDATE survey consisted of a customized questionnaire designed to collect data on sociodemographic and clinical characteristics and lifestyle, as well as responses to several validated HRQoL, work productivity, daily functioning, and self-esteem questionnaires. Responses to the Adult ADHD Self-Report Scale (ASRS) version 1.1 questionnaire ([@bibr20-1087054719841129]) incorporating the definition of ADHD from the Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.; *DSM*-IV-TR; [@bibr6-1087054719841129]) were also collected to assess symptoms of ADHD experienced in the past 6 months.

Respondents were divided into two groups: those who reported having received a diagnosis of ADHD by a health care provider at any point in their lives (ADHD-diagnosed respondents), and those who responded negatively when asked if they had ever received an ADHD diagnosis, but who had symptoms potentially consistent with ADHD based on their responses to the ASRS-V1.1 (symptomatic respondents). Women who were pregnant or who reported being pregnant over the 12 months preceding the study were excluded from the analysis.

Outcome measures that were compared between the two groups included the following: the Work Productivity and Activity Impairment: General Health (WPAI:GH) version 2.0 questionnaire; the Sheehan Disability Scale (SDS); the EuroQoL five-dimensional five-level (EQ-5D-5L) questionnaire; and the Rosenberg Self-Esteem Scale (RSES). Sociodemographic characteristics and reported comorbid physical and mental health conditions were also compared between the two groups.

Statistical Analyses {#section4-1087054719841129}
--------------------

To control for potential diagnosis selection bias, respondents diagnosed with ADHD were matched, according to sociodemographic characteristics and comorbid conditions, with a variable number of symptomatic respondents within the same sex-by-age group strata (ages 18-39, 40-54, and 55+ years) using propensity score matching ([@bibr28-1087054719841129]). The propensity score of diagnosis was estimated using separate logistic regressions for each sex-by-age group and included only baseline sociodemographic and comorbid condition covariates. Logistic regression covariates were entered in a stepwise fashion with a probability significance of *p* \< .1 for both entry and removal.

Respondents were matched by propensity score within each sex-by-age group stratum using variable optimal matching, with up to four controls per case ([@bibr32-1087054719841129]). The Statistical Analysis Software (SAS) VMATCH macro (SAS Institute Inc., Cary, NC, USA) was used for the matching based on Euclidean distances between cases and controls ([@bibr23-1087054719841129]).

The effect of ADHD diagnosis on each outcome measure was estimated using an indicator variable for the diagnosed group, and was adjusted for covariates that remained imbalanced after matching within at least one of the six sex-by-age group strata comparisons. A family-wise significance level of *p* \< .0085 was used for comparison tests based on Šidák's correction method. Generalized mixed models were fitted and implemented using the SAS MIXED procedure ([@bibr30-1087054719841129]), accounting for matched sets clustering. Non-linear mixed Tobit regression models were used for EQ-5D-5L index values to accommodate censoring of values at 1 (perfect health; [@bibr31-1087054719841129]; [@bibr33-1087054719841129]). Least-squares (LS) means (95% confidence intervals) for respondents diagnosed with ADHD and for those with symptomatic ADHD were provided, and the difference in the LS means was calculated.

All statistical tests were two sided and there was no *p*-value adjustment for multiple comparisons other than that mentioned above. Data were summarized using descriptive statistics (number of respondents \[*n*\], mean, standard deviation, median, minimum, and maximum) for continuous variables, and frequency and percentage for categorical variables.

Results {#section5-1087054719841129}
=======

Respondent Characteristics Before Matching {#section6-1087054719841129}
------------------------------------------

Of the 22,937 respondents to the VALIDATE survey, 444 participants had been diagnosed with ADHD and 1,055 participants reported ADHD-like symptoms but had no previous clinical diagnosis. Key sociodemographic, lifestyle, and comorbid condition characteristics before matching are summarized in [Table 1](#table1-1087054719841129){ref-type="table"}. Mean ages were 42.5 and 43.9 years (*p* = .070) for respondents diagnosed with ADHD and for those with symptomatic ADHD, respectively. In total, 53.4% of respondents diagnosed with ADHD and 46.9% of symptomatic respondents were men (*p* = .023). Other statistically significant differences in sociodemographic and lifestyle characteristics between groups before matching were the following: more respondents diagnosed with ADHD (86.7%) were of second or higher generation living in the United States compared with symptomatic respondents (77.3%; *p* \< .001), and respondents diagnosed with ADHD were more likely to be white (80.0% vs. 69.2%; *p* \< .001) or of mixed racial background (5.2% vs. 3.0%; *p* \< .001) and were more likely to be employed (55.2% vs. 47.4%; *p* = .024) than the symptomatic respondents ([Table 1](#table1-1087054719841129){ref-type="table"}).

###### 

Key Sociodemographic, Lifestyle, and Comorbid Condition Characteristics Among Unmatched Respondents Diagnosed With ADHD and With Symptomatic ADHD.

![](10.1177_1087054719841129-table1)

  Covariates                                              ADHD-diagnosed respondents (*n* = 444)   Symptomatic respondents (*n* = 1,055)   *p* value
  ------------------------------------------------------- ---------------------------------------- --------------------------------------- --------------------------------------------------------------
  Age                                                                                                                                      
   Mean (standard deviation)                              42.5 (13.9)                              43.9 (13.7)                             .070
   Median (minimum, maximum)                              42 (19, 86)                              44 (18, 84)                             ---
  Sex                                                                                                                                      
   Male                                                   237 (53.4)                               495 (46.9)                              .023[\*](#table-fn2-1087054719841129){ref-type="table-fn"}
  Familial generation in the United States                                                                                                 
   Non-U.S. born                                          7 (1.6)                                  65 (6.2)                                \<.001[\*](#table-fn2-1087054719841129){ref-type="table-fn"}
   First                                                  52 (11.7)                                175 (16.6)                              ---
   Second or higher                                       385 (86.7)                               815 (77.3)                              ---
  Race/ethnicity                                                                                                                           
   White                                                  355 (80.0)                               730 (69.2)                              \<.001[\*](#table-fn2-1087054719841129){ref-type="table-fn"}
   African American                                       31 (7.0)                                 124 (11.8)                              ---
   Hispanic                                               17 (3.8)                                 69 (6.5)                                ---
   Asian or Pacific Islander                              6 (1.4)                                  57 (5.4)                                ---
   Mixed racial background                                23 (5.2)                                 32 (3.0)                                ---
   Other                                                  12 (2.7)                                 43 (4.1)                                ---
  Highest education level                                                                                                                  
   Less than high school                                  20 (4.5)                                 39 (3.7)                                .380
   High school graduate or equivalent                     77 (17.3)                                223 (21.1)                              ---
   Attended college, did not graduate                     177 (39.9)                               429 (40.7)                              ---
   College graduate                                       118 (26.6)                               258 (24.5)                              ---
   Completed graduate school                              52 (11.7)                                106 (10.0)                              ---
  Annual household income                                                                                                                  
   \<US\$25,000                                           115 (25.9)                               286 (27.1)                              .514
   US\$25,000-US\$50,000                                  125 (28.1)                               328 (31.1)                              ---
   US\$50,000-US\$75,000                                  76 (17.1)                                173 (16.4)                              ---
   \>US\$75,000                                           115 (25.9)                               233 (22.1)                              ---
   Declined to answer                                     13 (2.9)                                 35 (3.3)                                ---
  Employment status                                                                                                                        
   Retired                                                45 (10.1)                                132 (12.5)                              .024[\*](#table-fn2-1087054719841129){ref-type="table-fn"}
   Student                                                36 (8.1)                                 69 (6.5)                                ---
   Employed                                               245 (55.2)                               500 (47.4)                              ---
   Unemployed                                             90 (20.3)                                269 (25.5)                              ---
   Homemaker                                              28 (6.3)                                 85 (8.1)                                ---
  Long-term disability                                                                                                                     
   Yes                                                    50 (11.3)                                168 (15.9)                              .020[\*](#table-fn2-1087054719841129){ref-type="table-fn"}
  Type of health insurance                                                                                                                 
   None                                                   93 (20.9)                                209 (19.8)                              .388
   Private                                                205 (46.2)                               445 (42.2)                              ---
   Government                                             113 (25.5)                               311 (29.5)                              ---
   Both                                                   24 (5.4)                                 59 (5.6)                                ---
   Other                                                  9 (2.0)                                  31 (2.9)                                ---
  Recreational drug use in the past 30 days                                                                                                
   Never in lifetime                                      214 (48.2)                               543 (51.5)                              .056
   Used but not in last 30 days                           166 (37.4)                               340 (32.2)                              ---
   Used 1-2 times                                         14 (3.2)                                 43 (4.1)                                ---
   Used 3-9 times                                         11 (2.5)                                 44 (4.2)                                ---
   Used 10-19 times                                       7 (1.6)                                  33 (3.1)                                ---
   Used ≥ 20 times                                        22 (5.0)                                 33 (3.1)                                ---
   Declined to answer/do not know                         10 (2.3)                                 19 (1.8)                                ---
  Comorbid conditions experienced in the past 12 months                                                                                    
   AN/BED/BN                                              34 (7.7)                                 63 (6.0)                                .250
   Anxiety                                                237 (53.4)                               613 (58.1)                              .098
   Chronic constipation                                   58 (13.1)                                146 (13.8)                              .742
   Depression                                             235 (52.9)                               649 (61.5)                              .002[\*](#table-fn2-1087054719841129){ref-type="table-fn"}
   Diabetes type 1 or 2                                   51 (11.5)                                152 (14.4)                              .137
   Dry eye                                                75 (16.9)                                219 (20.8)                              .088
   Emotional overeating/food addiction                    91 (20.5)                                238 (22.6)                              .412
   Hypertension                                           98 (22.1)                                291 (27.6)                              .028[\*](#table-fn2-1087054719841129){ref-type="table-fn"}
   Insomnia                                               170 (38.3)                               477 (45.2)                              .014[\*](#table-fn2-1087054719841129){ref-type="table-fn"}
   Migraine                                               122 (27.5)                               303 (28.7)                              .661
   OCD                                                    103 (23.2)                               161 (15.3)                              \<.001[\*](#table-fn2-1087054719841129){ref-type="table-fn"}
   Panic disorder                                         75 (16.9)                                214 (20.3)                              .133
   PTSD                                                   64 (14.4)                                143 (13.6)                              .682

*Note.* Data are *n* (%) unless otherwise stated. AN = anorexia nervosa; BED = binge eating disorder; BN = bulimia nervosa; OCD = obsessive--compulsive disorder; PTSD = post-traumatic stress disorder.

*p* \< .05 (*p* values calculated using two-sample *t*-tests and X^2^ tests for continuous and categorical variables, respectively).

Before matching, significant differences in the prevalence of comorbidities were observed between the two cohorts. Depression, hypertension, and insomnia were more common among respondents who were symptomatic than among those diagnosed with ADHD, whereas respondents diagnosed with ADHD had higher rates of obsessive-compulsive disorder.

Sociodemographic Characteristics, Comorbidities, and Lifestyle Variables After Matching {#section7-1087054719841129}
---------------------------------------------------------------------------------------

After matching, comparisons of covariates were conducted between respondents diagnosed with ADHD (*n* = 436) and symptomatic respondents (*n* = 867) within each of the six sex-by-age groups. Values for generations of family living in the United States (non-U.S. born, first generation, or second or higher generation) and rates of depression in the past 12 months were found to be significantly different (after correction for multiple comparisons) in at least one comparison (data not shown). These covariates were carried forward as independent variables in the subsequent regression models.

Comparing Outcomes After Matching {#section8-1087054719841129}
---------------------------------

Compared with symptomatic respondents, respondents with a formal diagnosis of ADHD had significantly better unadjusted mean scores for WPAI:GH Work Productivity Loss (29.32 vs. 49.15; *p* \< .001), WPAI:GH Activity Impairment (36.97 vs. 53.00; *p* \< .001) and significantly better mean SDS total and subscale scores (all *p* \< .001) ([Table 2](#table2-1087054719841129){ref-type="table"}). Respondents diagnosed with ADHD also had better unadjusted mean EQ-5D-5L Index (Utility) scores (0.78 vs. 0.70; *p* \< .001), EuroQoL visual analog scale (EQ VAS) Health State scores (72.46 vs. 65.05; *p* \< .001) and RSES scores (19.30 vs. 15.17; *p* \< .001) compared with symptomatic respondents ([Table 2](#table2-1087054719841129){ref-type="table"}). EQ-5D-5L subscale scores showed that respondents diagnosed with ADHD had significantly lower rates of problems associated with mobility, self-care, usual activities, pain/discomfort, and anxiety/depression than symptomatic respondents (*p* \< .05; data not shown).

###### 

Comparison of Outcomes Between Matched Respondents with Diagnosed ADHD and With Symptomatic ADHD (Unadjusted).

![](10.1177_1087054719841129-table2)

  Outcome                                                                                          *M* (*SD*) score   *p* value       
  ------------------------------------------------------------------------------------------------ ------------------ --------------- --------
  WPAI:GH Work Productivity Loss^[a](#table-fn4-1087054719841129){ref-type="table-fn"}^            29.32 (32.79)      49.15 (35.09)   \<.001
   WPAI:GH Absenteeism^[a](#table-fn4-1087054719841129){ref-type="table-fn"}^                      8.66 (20.81)       16.67 (25.21)   \<.001
   WPAI:GH Presenteeism^[a](#table-fn4-1087054719841129){ref-type="table-fn"}^                     25.70 (29.01)      44.53 (32.28)   \<.001
  WPAI:GH Activity Impairment                                                                      36.97 (31.87)      53.00 (31.46)   \<.001
  SDS total score^[b](#table-fn5-1087054719841129){ref-type="table-fn"}^                           9.91 (9.30)        14.92 (9.42)    \<.001
   SDS Work/School^[b](#table-fn5-1087054719841129){ref-type="table-fn"}^                          3.06 (3.36)        4.53 (3.58)     \<.001
   SDS Social Life^[b](#table-fn5-1087054719841129){ref-type="table-fn"}^                          3.44 (3.35)        5.26 (3.36)     \<.001
   SDS Family Life/Home Responsibilities^[b](#table-fn5-1087054719841129){ref-type="table-fn"}^    3.41 (3.26)        5.13 (3.30)     \<.001
  EQ-5D-5L Index (Utility) value^[c](#table-fn6-1087054719841129){ref-type="table-fn"}^            0.78 (0.17)        0.70 (0.20)     \<.001
  EQ VAS (Health State)^[d](#table-fn7-1087054719841129){ref-type="table-fn"}^                     72.46 (20.05)      65.05 (21.55)   \<.001
  Rosenberg Self-Esteem Scale total score^[e](#table-fn8-1087054719841129){ref-type="table-fn"}^   19.30 (6.55)       15.17 (6.32)    \<.001

*Note. p* values are derived from two-sample *t*-tests. WPAI:GH = Work Productivity and Activity Impairment questionnaire: General Health; SDS = Sheehan Disability Scale; EQ-5D-5L = EuroQoL five-dimensional, five-level questionnaire; EQ VAS = EuroQoL visual analog scale.

For employed respondents only (ADHD-diagnosed respondents, *n* = 172; symptomatic respondents, *n* = 232). WPAI:GH outcomes are expressed as impairment percentages; higher numbers indicate greater impairment and less productivity.

SDS total scores range from 0 (*unimpaired*) to 30 (*highly impaired*). Subscale scores range from 0 to 10; scores of ≥ 5 are associated with significant functional impairment.

EQ-5D Index (Utility) value summarizes EQ-5D-5L questionnaire responses as a single number on a scale anchored at 1 (*full health*) and 0 (*dead*).

Patients score their health state between 0 (*the worst imaginable health state*) and 100 (*the best imaginable health state*) on a 20 cm vertical graduated scale.

Total scores range from 0 to 30 with high scores reflecting strong self-esteem; a score \<15 may indicate problematic low self-esteem.

Relationship Between Diagnosis and Outcomes---Adjusted Analysis After Matching {#section9-1087054719841129}
------------------------------------------------------------------------------

LS means for WPAI:GH Productivity Loss and WPAI:GH Activity Impairment were significantly lower in respondents diagnosed with ADHD than in symptomatic respondents (WPAI:GH Productivity Loss, 39.37 vs. 55.62, respectively; WPAI:GH Activity Impairment, 41.73 vs. 55.78, respectively; *p* \< .001 for both). Respondents diagnosed with ADHD also had a significantly lower SDS total score (less impairment), higher self-rated health state based on the EQ-5D-5L, and higher RSES total score (better self esteem) than symptomatic respondents ([Table 3](#table3-1087054719841129){ref-type="table"}).

###### 

Comparison of Outcomes Between Matched Respondents With Diagnosed ADHD and With Symptomatic ADHD (Adjusted Least-Square Means Model).

![](10.1177_1087054719841129-table3)

  Diagnosis effect^[a](#table-fn10-1087054719841129){ref-type="table-fn"}^            Least-squares means (*SE*)   95% Confidence interval   *p* value
  ----------------------------------------------------------------------------------- ---------------------------- ------------------------- -----------
  Linear regression mixed model on matched sets                                                                                              
  WPAI:GH Productivity Loss^[b](#table-fn11-1087054719841129){ref-type="table-fn"}^                                                          \<.001
   ADHD diagnosed                                                                     39.37 (3.91)                 (31.67, 47.07)            
   Symptomatic ADHD                                                                   55.62 (3.33)                 (49.05, 62.18)            
   Difference                                                                         −16.25 (3.37)                (--22.88, --9.61)         
  WPAI:GH Activity Impairment                                                                                                                \<.001
   ADHD diagnosed                                                                     41.73 (2.12)                 (37.56, 45.90)            
   Symptomatic ADHD                                                                   55.78 (1.71)                 (52.42, 59.13)            
   Difference                                                                         −14.04 (1.78)                (--17.54, --10.55)        
  Sheehan Disability Scale total score                                                                                                       \<.001
   ADHD diagnosed                                                                     11.07 (0.64)                 (9.82, 12.32)             
   Symptomatic ADHD                                                                   15.55 (0.52)                 (14.53, 16.56)            
   Difference                                                                         −4.48 (0.52)                 (--5.50, --3.45)          
  EQ VAS (Health State)                                                                                                                      \<.001
   ADHD diagnosed                                                                     72.07 (1.40)                 (69.33, 74.81)            
   Symptomatic ADHD                                                                   65.55 (1.13)                 (63.33, 67.77)            
   Difference                                                                         6.52 (1.15)                  (4.27, 8.77)              
  Rosenberg Self-Esteem Scale total score                                                                          \<.0001                   
   ADHD diagnosed                                                                     18.78 (0.42)                 (17.97, 19.60)            
   Symptomatic ADHD                                                                   15.13 (0.34)                 (14.46, 15.79)            
   Difference                                                                         3.66 (0.33)                  (3.00, 4.31)              
  Tobit regression mixed model on matched sets                                                                                               
  EQ-5D-5L Index (Utility) value                                                                                                             \< .0001
   ADHD diagnosed                                                                     0.79 (0.01)                  (0.77, 0.81)              
   Symptomatic ADHD                                                                   0.72 (0.01)                  (0.71, 0.73)              
   Difference                                                                         0.07 (0.01)                  (0.04, 0.09)              

*Note.* WPAI:GH = Work Productivity and Activity Impairment questionnaire: General Health; EQ VAS = EuroQoL visual analog scale; EQ-5D-5L = EuroQoL five-dimensional, five-level questionnaire.

Models adjusted for generation in the United States (non-U.S. born, first generation, or second or higher generation) and experience of depression in past 12 months.

For employed respondents only (ADHD diagnosed respondents, *n* = 172; symptomatic respondents, *n* = 232).

Discussion {#section10-1087054719841129}
==========

In this nationally representative sample of U.S. adults, we demonstrate that the burden of ADHD is greater in adults with symptomatic ADHD who have not been clinically diagnosed than in adults who have received a formal diagnosis of ADHD. Compared with symptomatic individuals, those with an ADHD diagnosis performed significantly better in measures of work productivity, quality of life, functioning, and self-esteem. These findings highlight the importance of an evaluation and diagnosis in adults with symptoms of ADHD, and hence access to the resources and treatment that may serve to improve outcomes.

Employed respondents with symptomatic ADHD reported significantly higher levels of absenteeism, presenteeism, and overall work productivity loss compared with those with a diagnosis of ADHD, as measured by the WPAI:GH. For both cohorts, presenteeism made a greater contribution to the loss in overall work productivity than absenteeism. Accordingly, any economic costs associated with individuals being less productive while at work may be greater than those due to individuals missing work because of their health problems.

Individuals with symptomatic ADHD showed significantly greater functional impairment than those with a diagnosis across all three items of the SDS (Social Life, Family Life/Home Responsibilities, and Work/School). In both cohorts, the highest SDS score (greatest impairment) was observed for the Social Life item, suggesting that individuals with symptoms of ADHD may have greater difficulty in negotiating the external social environment than the home environment, where adaptation and adjustment to impairments may be easier.

EQ-5D-5L is a generic HRQoL instrument that has been shown to be sensitive to ADHD in children ([@bibr13-1087054719841129]). Studies that have used the EQ-5D-5L instrument to assess the impact of ADHD on HRQoL in adults have recruited populations with a high rate of psychiatric comorbidities ([@bibr19-1087054719841129]; [@bibr24-1087054719841129]). In the present study, adults with symptomatic ADHD reported a significantly lower HRQoL than respondents diagnosed with ADHD. Similarly, RSES scores indicated lower self-esteem in the symptomatic respondents compared with those reporting a previous diagnosis of ADHD.

Few data have been published on the impact of the lack of a diagnosis in adults exhibiting ADHD-like symptoms. A study by [@bibr1-1087054719841129] compared adults with symptoms of ADHD but no formal diagnosis, individuals with an ADHD diagnosis and adults without ADHD ([@bibr1-1087054719841129]). Adults without symptoms of ADHD reported lower rates of a previous history of psychiatric disorders and current depression than both the diagnosed and undiagnosed adults with symptoms of ADHD. In contrast to the present study, Able et al. found no significant differences in impairment between diagnosed and undiagnosed adults with symptoms of ADHD using the SDS. Of note, baseline characteristics (including age, race, educational level, socioeconomic factors, and comorbidities) differed between these two studies. In particular, Able et al. found similar rates of current depression between the respondents diagnosed with ADHD and those with symptoms that were undiagnosed, whereas, in the present study, rates of depression in the past 12 months were higher in adults with symptomatic ADHD. Furthermore, the two studies differed in design. The Able et al. study involved a fully insured managed care population ([@bibr1-1087054719841129]), whereas 20% of participants in the VALIDATE study were uninsured and the remainder had a variety of insurance plans. Also, participants in the previous study were allocated to cohorts based on claims data (medical claims and drug use) and ADHD screen ([@bibr1-1087054719841129]); in the VALIDATE study, however, groups were designated according to self-reported data. Importantly, unlike the Able et al. study, the present study used matching and adjusting methodologies to reduce the risk of confounding and selection bias.

There are several possible reasons as to why adults experiencing symptomatic ADHD may not seek a formal evaluation, including lack of awareness, underrecognition of symptoms, development of coping mechanisms, and adoption of a lifestyle that compensates for ADHD-related impairments. Such symptoms may also overlap with those of depression or anxiety, leading to a misdiagnosis or a lack of formal diagnosis ([@bibr8-1087054719841129]). From a health care perspective, primary care physicians are often untrained in the use of diagnostic or assessment tools to evaluate adults with suspected ADHD, and may feel less comfortable managing the disorder in adults than in children ([@bibr15-1087054719841129]). Primary care physicians have been shown to be significantly less likely than psychiatrists to make an initial diagnosis of ADHD in adults if no pediatric ADHD diagnosis had previously been made ([@bibr16-1087054719841129]). The present data demonstrate that improving the rate of diagnosis of ADHD in adults could yield benefits both to the affected individuals and to society.

The strengths of this retrospective study include the recruitment of a large, real-world population of nationally representative adults and the breadth of the outcome measures analyzed. However, the data should be interpreted in the light of a number of caveats. First, ADHD diagnosis, symptoms, and comorbid conditions were self-reported and no further clinical confirmation was provided. Second, respondents were screened for symptoms of ADHD using the ASRS, a self-reported instrument that is based on only a partial list of *DSM*-IV-TR-based questions; additional *DSM*-IV-TR criteria for ADHD in adults, including symptoms before the age of 7 years, presence of some impairment from symptoms in two or more settings, evidence of impaired functioning, and symptoms that cannot be explained by other psychiatric disorders, were not applied in this study ([@bibr5-1087054719841129]). Indeed, in this study, significantly greater proportions of respondents in the symptomatic group had experienced depression, hypertension or insomnia in the past 12 months compared those with an ADHD diagnosis. Nevertheless, although it is not a substitute for clinical diagnosis, the ASRS can provide a useful screening tool to assess the occurrence and severity of symptoms that may warrant further in-depth evaluation ([@bibr1-1087054719841129]; [@bibr2-1087054719841129]). Third, the study was based on a self-selected sample, which may limit the generalizability of the results. Finally, as a cross-sectional study, any conclusions related to temporal or causal relationships should be made with caution.

Conclusion {#section11-1087054719841129}
==========

These analyses of the VALIDATE study data compared the burden of ADHD in U.S. adults who reported having been diagnosed with the condition with that in symptomatic but undiagnosed adults. This comparison revealed that individuals who had been diagnosed with ADHD were more likely to experience better functioning, HRQoL, and self-esteem than those with symptomatic ADHD. This result appears to be robust, withstanding several levels of increasingly rigorous statistical adjustment. However, these findings should be confirmed by additional studies employing equally rigorous statistical methods.
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